Simplify single-use systems with AseptiQuik? genderless connectors from CPC. Innovative design eliminates separate male and female components to reduce system complexity and inventory requirements, while increasing process flexibility
AseptiQuik® connectors from CPC make single-use sterile connections faster, easier and safer than ever before.Robust, easy-to-use connector designs enable users to quickly transfer valuable media with more confidence and less risk of operator error. AseptiQuik® connectors provide reliable, sterile connections without the need for clamps, fixtures or tube welding.
The newest addition to CPC’s sterile connection technologies, genderless AseptiQuik® G connectors simplify single-use systems design and process integration. Our innovative design eliminates separate male and female components to substantially reduce complexity and support modular system design. Because the connectors are interchangeable—any single-use G series connector mates with any other G series connector—systems are more flexible and minimize supply chain complexity.
The AseptiQuik family offers the broadest range of single-use sterile connectors in the industry with flow configurations from 3.2mm to 25.4mm (1/8” to 1”). AseptiQuik’s are ideal for applications where reliability and sterility are a must—including single-use bag and tubing assemblies, cell banking systems, bioreactors, mixers, sampling, formulation and filling. See the AseptiQuikvideos.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.